Abstract
National and sub-national population-based surveys, when performed at intervals, may assess important changes in TB prevalence. In 2022 we re-surveyed nine Nairobi County neighbourhoods that were previously surveyed in 2015. We aimed to determine pulmonary TB prevalence, compare prevalence to 2015 estimates, and evaluate changes in risk groups. Participants who reported cough of any duration and/or whose chest x-ray suggested TB submitted sputum for smear microscopy, Xpert Ultra, and liquid culture. We defined prevalent TB as Mycobacterium tuberculosis detection by sputum Xpert or culture, excepting individuals who were only trace positive. Our methods differed from 2015, which used solid media, Xpert MTB/RIF, and cough duration >2 weeks. We calculated TB prevalence using random-effects logistic regression models with missing value imputations and inverse probability weighting. In 2022 among 6369 participants, 1582 submitted >1 sputum sample, among whom 42 (2·7%) had TB, a weighted TB prevalence of 806/100,000 (95% confidence interval (CI), 518-1096). An additional 31 (2·0%) participants tested Ultra trace-positive/culture-negative. For comparison to 2015, we excluded 2022 participants (n=2) whose only criterion for sputum was cough <2 weeks. There was no evidence for a decline in overall TB prevalence from 2015 to 2022. TB prevalence among men was high (1368/100,000) but unchanged compared to 2015 (p-value = 0·50). The age group with the highest estimated prevalence remained people ages 45–54 years. Among people with prevalent TB who reported cough, 76% had not sought health care. Dissimilar from other serial surveys that showed declines in TB prevalence, we found persistently high TB prevalence over a 7-year period in Nairobi County. Limitations of this study include changes in methodology between the two surveys and complex effects of the COVID-19 pandemic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was funded by the National Institutes of Health/NIAID (NIH grant 5R01AI150815 – DJH, TRH, VN), the National Center for Advancing Translational Sciences of the NIH (UL1 TR002319), NIH D43 TW011817-01 (VN, CK, DJH, TRH), and the Firland Foundation (TRH). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Institutional Review Boards of KEMRI (KEMRI/SERU/3988) and the University of Washington (UW STUDY00009209).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data are available on request from Kenya Medical Research Institute (KEMRI).
